United Therapeutics Quick Ratio (UTHR) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


United Therapeutics Corporation  (NASDAQ: UTHR)

United Therapeutics's Quick Ratio

UTHR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 5.51 above United Therapeutics Corporation average.

Within Major Pharmaceutical Preparations industry 165 other companies have achieved higher Quick Ratio than United Therapeutics in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 424 to 704.

Explain Quick Ratio?
How much Cash & cash equivalents UTHR´s has?
What are UTHR´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UTHR/financial-strength
https://api.csimarket.com/api/v1/companies/UTHR/fundamentals
https://api.csimarket.com/api/v1/companies/UTHR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
UTHR Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 14.28 %
Y / Y Cash & cash equivalent Change 24.29 %
Quick Ratio MRQ 5.51
UTHR's Total Ranking # 704
Seq. Current Liabilities Change 2.71 %
Seq. Cash & cash equivalent Change -7.65 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 261
Overall Market # 704


Quick Ratio Statistics
High Average Low
10.82 4.6 0.83
(Dec 31 2022)   (Dec 31 2010)




Financial Statements
United Therapeutics's Current Liabilities $ 624 Millions Visit UTHR's Balance sheet
United Therapeutics's Cash & cash equivalent $ 3,440 Millions Visit UTHR's Balance sheet
Source of UTHR's Sales Visit UTHR's Sales by Geography


Cumulative United Therapeutics's Quick Ratio

UTHR's Quick Ratio for the trailling 12 Months

UTHR Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -5.16 %
Y / Y Cash & cash equivalent TTM Growth -1.34 %
Quick Ratio TTM 5.12
Total Ranking TTM # 3655
Seq. Current Liabilities TTM Growth 3.37 %
Seq. Cash & cash equivalent TTM Growth 5.81 %


On the trailing twelve months basis UTHR Cash & cash equivalent grew by 24.29 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in United Therapeutics's Quick Ratio to 5.12, above UTHR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 425 other companies have achieved higher Quick Ratio than United Therapeutics. While Quick Ratio overall ranking has improved so far to 3655, from total ranking during the twelve months ending second quarter 2026 at 3663.

Explain Quick Ratio?
How much Cash & cash equivalents UTHR´s has?
What are UTHR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 426
Healthcare Sector # 865
Within the Market # 3655


trailing twelve months Quick Ratio Statistics
High Average Low
8.12 3.69 1.01
(Jun 30 2023)   (Sep 30 2014)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Structure Therapeutics Inc   11.62 $ 1,244.661  Millions$ 107.104  Millions
Immunome Inc   11.27 $ 461.582  Millions$ 40.966  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions
Xenon Pharmaceuticals Inc   10.99 $ 950.798  Millions$ 86.487  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Abcellera Biologics Inc   10.85 $ 764.424  Millions$ 70.473  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions
Bicycle Therapeutics Plc  10.57 $ 469.928  Millions$ 44.459  Millions
Lipocine Inc   10.55 $ 21.455  Millions$ 2.034  Millions
Cyclerion Therapeutics Inc   10.32 $ 456.221  Millions$ 44.197  Millions
Lexicon Pharmaceuticals Inc   10.31 $ 183.203  Millions$ 17.773  Millions
Adicet Bio Inc   10.28 $ 174.779  Millions$ 16.996  Millions
An2 Therapeutics Inc   10.26 $ 64.400  Millions$ 6.275  Millions
Pmv Pharmaceuticals Inc   10.15 $ 108.515  Millions$ 10.689  Millions
Nuvectis Pharma inc   9.91 $ 140.707  Millions$ 14.193  Millions
Renovorx Inc   9.76 $ 20.404  Millions$ 2.091  Millions

Date modified: 2026-11-06T12:55:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.